--- title: "Theralase Bladder Cancer Data to Debut at 2026 European Urology Congress" type: "News" locale: "en" url: "https://longbridge.com/en/news/276140908.md" description: "Theralase Technologies (TSE:TLT) announced that its interim clinical data on Ruvidar therapy for bladder cancer will be presented at the 2026 European Urology Congress. The data shows a two-thirds complete response rate and durable responses lasting over 15 months. Theralase plans to submit clinical data to Health Canada and the U.S. FDA in Q3 2026, aiming for approval in 2027. Analysts rate TLT stock as a Hold with a C$0.25 price target, citing weak financial performance but some technical support. Theralase focuses on developing energy-activated therapies for cancer treatment." datetime: "2026-02-17T15:10:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276140908.md) - [en](https://longbridge.com/en/news/276140908.md) - [zh-HK](https://longbridge.com/zh-HK/news/276140908.md) --- # Theralase Bladder Cancer Data to Debut at 2026 European Urology Congress ### President's Day Sale - 70% Off - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Theralase Technologies ( (TSE:TLT) ) has issued an announcement. Theralase Technologies’ interim clinical data on its light-activated Ruvidar therapy for Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ has been selected for oral presentation at the 2026 European Association of Urology Congress in London. The acceptance underscores growing clinical interest in the company’s technology within the international urology community and highlights its bid to position Ruvidar as a bladder-preserving option for patients facing radical cystectomy. Interim results from the completed international Phase II study show encouraging safety and efficacy signals, including a two-thirds complete response rate and durable responses lasting 15 months or more in some patients, with at least one patient maintaining response beyond three years after a single treatment. With enrollment finished, Theralase plans to begin rolling submissions of the clinical data to Health Canada and the U.S. FDA in the third quarter of 2026, aiming for potential approval and initial commercialization in Canada and the United States in 2027, which could materially reshape treatment options for high-risk bladder cancer patients. The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page. **Spark’s Take on TSE:TLT Stock** According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral. The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield. To see Spark’s full report on TSE:TLT stock, click here. **More about Theralase Technologies** Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on developing energy-activated small molecules for the destruction of cancer, bacteria and viruses. The company is currently advancing Ruvidar (TLD-1433), a light-activated drug used with its TLC-3200 medical laser system, with a key market focus on high-grade, high-risk non-muscle invasive bladder cancer patients who have exhausted standard therapies. **Average Trading Volume:** 224,782 **Technical Sentiment Signal:** Strong Buy **Current Market Cap:** C$77.12M ### Related Stocks - [THTX.US](https://longbridge.com/en/quote/THTX.US.md) ## Related News & Research - [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md) - [Tajiri Resources adds C$2M concurrent offering to ongoing financing](https://longbridge.com/en/news/282635478.md) - [Invivyd rises after update from late-stage trial for COVID therapy](https://longbridge.com/en/news/282283891.md) - [](https://longbridge.com/en/news/282355594.md) - [09:31 ETIASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer](https://longbridge.com/en/news/282353448.md)